Developing structure-activity relationships for the prediction of hepatotoxicity

Chemical Research in Toxicology

Volumn 23, Issue 7, 2010, Pages 1215-1222

  Greene, Nigel ^a   Fisk, Lilia ^b   Naven, Russell T ^a   Note, Reine R ^b,c   Patel, Mukesh L ^b   Pelletier, Dennis J ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b LHASA LIMITED   (United Kingdom)

^c L ORÉAL RECHERCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; COCAINE; CODEINE; DIAMORPHINE; MORPHINE; PIOGLITAZONE; ROSIGLITAZONE; THIOPHENE; TICLOPIDINE; TIENILIC ACID; TROGLITAZONE; ZILEUTON;

ARTICLE; COMPUTER MODEL; DRUG INDUCED DISEASE; EXPERT SYSTEM; HUMAN; LIVER INJURY; LIVER TOXICITY; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION;

DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRACYCLINES; THIOPHENES;

EID: 77955362472     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx1000865     Document Type: Article

References (45)

1. Holt, M. P. and Ju, C. (2006) Mechanisms of drug-induced liver injury AAPS J. 8, E48-E54
2. Kaplowitz, N. (2005) Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discovery 4, 489-499
3. Williams, D. P. (2006) Toxicophores: investigations in drug safety Toxicology 226, 1-11
4. Zimmerman, H. J. (1999) The Adverse Effects of Drugs and Other Chemicals on the Liver (Zimmerman, H. J., Ed.) Lippincott Williams & Wilkins, Philadelphia.
5. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 3, 711-716
6. Pirmohamed, M. (2006) Genetic factors in the predisposition to drug-induced hypersensitivity reactions AAPS J. 8, E20-E26
7. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6, 161-225
8. Cheng, A. and Dixon, S. L. (2003) In silico models for the prediction of dose-dependent human hepatotoxicity J. Comput.-Aided Mol. Des. 17, 811-823
9. Li, A. P. (2004) An integrated, multidisciplinary approach for drug safety assessment Drug Discovery Today 9, 687-693
10. Greene, N. and Naven, R. (2009) Early toxicity screening strategies Curr. Opin. Drug Discovery Dev. 12, 90-97
11. Dobo, K. L., Greene, N., Cyr, M. O., Caron, S., and Ku, W. W. (2006) The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development Regul. Toxicol. Pharmacol. 44, 282-293
12. Greene, N. (2002) Computer systems for the prediction of toxicity: An update Adv. Drug Delivery Rev. 54, 417-431
13. Simon-Hettich, B., Rothfuss, A., and Steger-Hartmann, T. (2006) Use of computer-assisted prediction of toxic effects of chemical substances Toxicology 224, 156-162
14. Pearl, G. M., Livingston-Carr, S., and Durham, S. K. (2001) Integration of computational analysis as a sentinel tool in toxicological assessments Curr. Top. Med. Chem. 1, 247-255
15. Matthews, E. J., Kruhlak, N. L., Benz, R. D., and Contrera, J. F. (2004) Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data Curr. Drug Discovery Technol. 1, 61-76
16. Matthews, E. J., Ursem, C. J., Kruhlak, N. L., Benz, R. D., SabateÌ, D. A., Yang, C., Klopman, G., and Contrera, J. F. (2009) Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities Regul. Toxicol. Pharmacol. 54, 23-42
17. Matthews, E. J., Kruhlak, N. L., Benz, R. D., SabateÌ, D. A., Marchant, C. A., and Contrera, J. F. (2009) Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C. Use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities Regul. Toxicol. Pharmacol. 54, 43-65
18. Engelmore, R. S. and Feigenbaum, E. (1993) Knowledge-based systems in Japan; http://www.wtec.org/loyola/kb/toc.htm (accessed January 27, 2010).
19. Saunders, M. C., Sullivan, T. J., Nash, B. L., Tonnessen, K. A., and Miller, B. J. (2005) A knowledge-based approach for classifying lake water chemistry Knowledge-Based Syst. 18, 47-54
20. Judson, P. N., Marchant, C. A., and Vessey, J. D. (2003) Using argumentation for absolute reasoning about the potential toxicity of chemicals J. Chem. Inf. Comput. Sci. 43, 1364-1370
21. Langton, K., Patlewicz, G. Y., Long, A., Marchant, C. A., and Basketter, D. A. (2006) Structure-activity relationships for skin sensitization: Recent improvements to Derek for Windows Contact Dermatitis 55, 342-347
22. Ludwig, J. and Axelsen, R. (1983) Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases Dig. Dis. Sci. 28, 651-666
23. Lee, W. M. (2003) Drug-induced hepatotoxicity N. Engl. J. Med. 349, 474-485
24. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008) Cellular imaging predictions of clinical drug-induced liver injury Toxicol. Sci. 105, 97-105
25. Chopra, I. and Roberts, M. (2001) Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance Microbiol. Mol. Biol. Rev. 65, 232-260
26. Zimmerman, H. J., Lewis, J. H., Ishak, K. G., and Maddrey, W. C. (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases Hepatology 4, 315-323
27. Joshi, E. M., Heasley, B. H., Chordia, M. D., and Macdonald, T. L. (2004) In vitro metabolism of 2-acetylbenzothiophene: Relevance to zileuton hepatotoxicity Chem. Res. Toxicol. 17, 137-143
28. Leone, N., Giodanino, C., Baronio, M., Morgando, A., David, E., and Rizzetto, M. (2004) Ticlopidine-induced cholestatic hepatitis successfully treated with corticosteroids: A case report Hepatol. Res. 28, 109-112
29. McMurtry, R. J. and Mitchell, J. R. (1977) Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine Toxicol. Appl. Pharmacol. 42, 285-300
30. Dalvie, D. K., Kalgutkar, A. S., Khojasteh-Bakht, S. C., Obach, R. S., and O'Donnell, J. P. (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings Chem. Res. Toxicol. 15, 269-299
31. Beaune, P. H. and Lecoeur, S. (1997) Immunotoxicology of the liver: adverse reactions to drugs J. Hepatol. 26, 37-42
32. O'Donnell, J. P., Dalvie, D. K., Kalgutkar, A. S., and Obach, R. S. (2003) Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen Drug Metab. Dispos. 31, 1369-1377
33. Wiley, R. A., Traiger, G. J., Baraban, S., and Gammal, L. M. (1984) Toxicity-distribution relationships among 3-alkylfurans in mouse liver and kidney Toxicol. Appl. Pharmacol. 74, 1-9
34. Boess, F., Ndikum-Moffor, F. M., Boelsterli, U. A., and Roberts, S. M. (2000) Effects of cocaine and its oxidative metabolites on mitochondrial respiration and generation of reactive oxygen species Biochem. Pharmacol. 60, 615-623
35. Ndikum-Moffor, F. M., Schoeb, T. R., and Roberts, S. M. (1998) Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine J. Pharmacol. Exp. Ther. 284, 413-419
36. Nagamatsu, K., Terao, T., and Toki, S. (1985) In vitro formation of codeinone from codeine by rat or guinea pig liver homogenate and its acute toxicity in mice Biochem. Pharmacol. 34, 3143-3146
37. Todaka, T., Ishida, T., Kita, H., Narimatsu, S., and Yamano, S. (2005) Bioactivation of morphine in human liver: isolation and identification of morphinone, a toxic metabolite Biol. Pharm. Bull. 28, 1275-1280
38. Pan, J., Zhang, Q., Zhang, Y., Ouyang, Z., Zheng, Q., and Zheng, R. (2005) Oxidative stress in heroin administered mice and natural antioxidants protection Life Sci. 77, 183-193
39. Nadanaciva, S., Dykens, J. A., Bernal, A., Capaldi, R. A., and Will, Y. (2007) Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration Toxicol. Appl. Pharmacol. 223, 277-287
40. Kalgutkar, A. S., Vaz, A. D. N., Lame, M. E., Henne, K. R., Soglia, J., Zhao, S. X., Abramov, Y. A., Lombardo, F., Collin, C., Hendsch, Z. S., and Hop, C. E. C. A. (2005) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4 Drug Metab. Dispos. 33, 243-253
41. Wen, B., Ma, L., Rodrigues, A. D., and Zhu, M. (2008) Detection of novel reactive metabolites of trazodone: Evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine Drug Metab. Dispos. 36, 841-850
42. Bauman, J. N., Frederick, K. S., Sawant, A., Walsky, R. L., Cox, L. M., Obach, R. S., and Kalgutkar, A. S. (2008) Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug Drug Metab. Dispos. 36, 1016-1029
43. Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., and Will, Y. (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone Toxicol. Sci. 103, 335-345
44. Benjamin, S. B., Ishak, K. G., Zimmerman, H. J., and Grushka, A. (1981) Phenylbutazone liver injury: A clinical-pathologic survey of 23 cases and review of the literature Hepatology 1, 255-263
45. Marchant, C. A., Fisk, L., Note, R. R., Patel, M. L., and Suarez, D. (2009) An expert system approach to the assessment of hepatotoxicity potential Chem. Biodiversity 6, 2107-2114